Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Core Scientific (CORZ) Other financing activities (2021 - 2026)

Core Scientific has reported Other financing activities over the past 3 years, most recently at $882000.0 for Q1 2026.

Quarterly results put Other financing activities at $882000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was -$334000.0 (up 72.53% YoY), and the annual figure for FY2024 was $1.3 million, changed.
Other financing activities reached $882000.0 in Q1 2026 per CORZ's latest filing, up from -$1.2 million in the prior quarter.
Across five years, Other financing activities topped out at $882000.0 in Q1 2026 and bottomed at -$1.2 million in Q4 2024.